

1 **BENEFIT-RISK ASSESSMENT OF COVID-19 VACCINE, MRNA (MRNA-1273)**
2 **FOR MALES AGE 18-64 YEARS**

3

4 **Osman N. Yogurtcu^a, Patrick R. Funk^a, Richard A. Forshee^a, Steven A. Anderson^a, Peter W. Marks^{b,c},**
5 **Hong Yang^{a*}**

6

7 ^aOffice of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA

8 ^bOffice of Vaccines Research and Review, Center for Biologics Evaluation and Research, USFDA, Silver Spring, MD, USA

9 ^cOffice of the Center Director, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA

10

11 **ABSTRACT**

12 Since authorization of the Moderna mRNA COVID-19 Vaccine, real-world evidence has indicated its
13 effectiveness in preventing COVID-19 cases. However, increased cases of mRNA vaccine-associated
14 myocarditis/pericarditis have been reported, predominantly in young adults and adolescents. The Food
15 and Drug Administration conducted benefit-risk assessment to inform review of the Biologics License
16 Application for use of the Moderna vaccine among individuals ages 18 years and older. We modeled
17 benefit-risk per million individuals who receive two complete doses of the vaccine. Benefit endpoints
18 were vaccine-preventable COVID-19 cases, hospitalizations, intensive care unit (ICU) admissions, and
19 deaths. The risk endpoints were vaccine-related myocarditis/pericarditis cases, hospitalizations, ICU
20 admissions and deaths. The analysis was conducted on the age-stratified male population, due to data
21 signals and previous work showing males to be the main risk group. We constructed six scenarios to

1

22 evaluate the impact of uncertainty associated with pandemic dynamics, vaccine effectiveness (VE)
23 against novel variants, and rates of vaccine-associated myocarditis/pericarditis cases on the model
24 results. For our most likely scenario, we assumed the US COVID-19 incidence was for the week of
25 December 25, 2021, and a VE of 30% against cases and 72% against hospitalization with the Omicron-
26 dominant strain. Our source for estimating vaccine-attributable myocarditis/pericarditis rates was
27 FDA's CBER Biologics Effectiveness and Safety (BEST) System databases. Overall, our results supported
28 the conclusion that the benefits of the vaccine outweigh its risks. Remarkably, we predicted vaccinating
29 one million 18-25 year-old males would prevent 82,484 cases, 4,766 hospitalizations, 1,144 ICU
30 admissions, and 51 deaths due to COVID-19, comparing to 128 vaccine-attributable
31 myocarditis/pericarditis cases, 110 hospitalizations, zero ICU admissions, and zero deaths.
32 Uncertainties in the pandemic trajectory, effectiveness of vaccine against novel variants, and vaccine-
33 attributable myocarditis/pericarditis rate are important limitations of our analysis. Also, the model
34 does not evaluate potential long-term adverse effects due to either COVID-19 or vaccine-attributable
35 myocarditis/pericarditis.

36 **Correspondence:** Hong.Yang@fda.hhs.gov (Office of Biostatistics & Pharmacovigilance, FDA - Center for
37 Biologics Evaluation and Research, 10903 New Hampshire Ave, WO71, Silver Spring, MD 20993-0002
38 USA)

39 **Keywords** COVID-19 Vaccine · FDA · Benefit-Risk Analysis · Males · Myocarditis · Pericarditis

40

41

42 1. Introduction

43 The Moderna COVID-19 mRNA (mRNA-1273) vaccine has been available for use in persons 18 years of
44 age and older in the United States under Emergency Use Authorization (EUA) and was recently licensed
45 in January 2022. Since authorization of mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) in
46 December of 2020, real-world evidence from the pre-Omicron period has indicated the vaccines
47 effectively prevent COVID-19 cases, hospitalizations, and deaths. However, cases of myocarditis and
48 pericarditis associated with mRNA COVID-19 vaccines have been reported in the United States (US),
49 especially in adolescents (for whom the Pfizer-BioNTech vaccine is authorized) and young adult males¹⁻³
50 through the Biologics Effectiveness and Safety (BEST) system which is an active post-market
51 surveillance system at the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and
52 Research (CBER). CBER follows FDA's structured framework¹⁶ when making decisions on product
53 licensure. FDA previously conducted and published a benefit-risk assessment for use of COMIRNATY
54 among ages 16 years and older⁶. In this paper, to advance the transparency regarding FDA's decision-
55 making process, we report its benefit-risk (B-R) assessment (using principles similar to FDA⁶ and CDC's⁴
56 earlier assessment for a different vaccine) to inform regulatory decisions related to the Biologics
57 License Application (BLA) for use of the Moderna vaccine among individuals 18 years of age and older.

58 The regulatory question addressed by our analyses is whether the benefits of vaccination
59 outweigh the risks for the target population, considering the uncertainties of the evolving pandemic
60 (changes in disease incidence and emergence of new variants) and the risk of myocarditis/pericarditis
61 after vaccination, predominantly among young males, identified by post-authorization safety
62 surveillance. Our assessment used the structured benefit-risk framework (BRF) including four key
63 dimensions - Analysis of Condition, Current Treatment Options, Benefits, and Risks and Risk
64 Management⁵. We assessed the benefits and risks per million males ages 18-64 years who are

65 vaccinated with two complete doses of the Moderna vaccine. The metric is fixed at per one million
66 individuals with two complete primary doses of vaccination) to compare benefits and risks consistently
67 among the groups without knowing how vaccine uptake may vary. We estimated COVID-19 cases,
68 hospitalizations, ICU admissions, and deaths prevented by the vaccination (benefits) and
69 myocarditis/pericarditis cases, related hospitalizations, ICU admissions, and deaths attributable to the
70 vaccine (risks). We chose these endpoints as they are the most clear and measurable endpoints for
71 benefits and risks that have the greatest public health significance. Modeling was not conducted for
72 females and individuals 65 years of age and older due to previous work showing a relative lower risk⁶
73 among these groups, resulting in too few cases of myocarditis/pericarditis after vaccination in these
74 groups to reliably estimate myocarditis/pericarditis rates. These groups are also expected to have more
75 favorable benefit-risk compared to males age 18-64 years based on available evidence.

76 2. Methods

77 2.1. Model Overview

78 We used similar methodology as presented in our earlier paper⁶. Details of our calculation may be seen
79 in our Microsoft Excel model file in the Supplementary. We assessed the benefits and risks per million
80 male population stratified by age: 18-25, 26-35, 36-45, 46-55 and 56-64 years since data indicated an
81 age-dependent risk of myocarditis and pericarditis post vaccination. Those age groups aligned with the
82 data collection stratification for COVID-19 outcomes. The model benefit endpoints were vaccine-
83 preventable COVID-19 cases, hospitalizations, intensive care unit (ICU) admissions, and deaths. The
84 model risk endpoints were vaccine related myocarditis/pericarditis cases, hospitalizations, ICU
85 admissions, and deaths (Figure 1). Key model inputs include duration of vaccine protection, VE against
86 COVID-19 cases and hospitalizations, age-specific COVID-19 case and hospitalization incidence rates,

87 age-specific vaccine-attributable myocarditis case rate, hospitalizations, ICU admissions, and death
88 rate.

89 Our model produced benefit-risk outcomes for six different scenarios (Table 1) as a sensitivity
90 analysis of the uncertainties related to three major model inputs, COVID-19 incidence rate (Scenarios 1,
91 2, and 3), VE (Scenarios 1 and 4), and vaccine-attributable myocarditis/pericarditis rate (Scenarios 1, 5,
92 and 6). We decide to use Scenario 1 as a base scenario since it represents the most-up-to date COVID-
93 19 incidence at the time of this analysis. For the remaining scenarios, only one of the three major
94 model inputs from Scenario 1 is modified at a time (summarized in Table 1). Model predictions are
95 provided in Table 2. Visual benefit-risk plot for age groups 18-25, 26-35, and 36-45 for Scenario 1 is
96 shown on Figure 2.

97 2.2. Benefits

98 2.2.1. Data and assumptions

99 2.2.1.1. Duration of vaccine protection

100 We estimated protection over a 5-month period after completion of the 2-dose primary series, since a
101 5-month interval between completion of the primary series and booster dose is authorized by FDA and
102 recommended by the Centers for Disease Control and Prevention (CDC). For simplicity, the model did
103 not account for benefits of partial vaccination and assumes a constant VE during the 5-month period
104 post second dose. We did not factor in protection from potential exposure or infection with COVID-19
105 among unvaccinated individuals into our analysis since the degree of this protection and its time-
106 dependency were not well understood at the time of analysis.

107 2.2.1.2. Incidences of COVID-19 case, hospitalization, ICU, and death

108 The COVID-19 case and hospitalization incidence rates were assumed to remain constant over the

109 assessment period (within 5 months post-second dose). For Scenarios 1, 4, 5, and 6, the crude
110 incidence rates of COVID-19 cases and deaths in the unvaccinated population from the week of
111 December 25, 2021, were obtained from the COVID Data Tracker for all male age groups⁸. The
112 hospitalization rates for these scenarios were for the week of December 25, 2021, collected by COVID-
113 NET⁷. The percentage of hospitalizations with ICU admission was estimated based on the cumulative
114 rates of ICU admissions for each male age group from March 2020 to October 2021 provided by the
115 CDC (collected by COVID-NET). We used the average 2021 US COVID-19 incidence rate and the lowest
116 US COVID-19 incidence rate (June 2021) in Scenarios 2 and 3, respectively. All the incidence-related
117 model inputs are summarized in Table 3.

118 2.2.1.3. Vaccine effectiveness

119 We assumed Omicron as the dominant strain in Scenarios 1, 2, 3, 5, and 6 and assumed averages of
120 30% VE against COVID-19 cases and 72% VE against COVID-19 hospitalizations during the 5-month
121 period post second dose. The data from a UK surveillance report were used to derive these VEs for
122 Omicron⁹. For Scenario 4 we assume Delta as the dominant strain and used the US averages of 80% VE
123 against cases and 90% VE against hospitalizations¹⁰. Many studies conducted in the US and other
124 countries during the Delta-dominant period showed consistently high VE of the Moderna vaccine
125 against both COVID-19 cases and related hospitalization^{10,11}. For all scenarios, we assumed the vaccine
126 effectiveness against death due to COVID-19 would be equal to the vaccine effectiveness against
127 hospitalizations due to COVID-19.

128 2.3. Risks

129 2.3.1. Calculation of risks

130 Our benefit-risk model had four risk endpoints (Figure 1): vaccine-attributable myocarditis/pericarditis

131 cases, hospitalizations, ICU admissions, and deaths. Estimates of vaccine-attributable cases of
132 myocarditis/pericarditis (per 1 million person-days with a risk window of 7 days post vaccination) were
133 based on a meta-analysis of four health claims databases in BEST, which combined data from four data
134 partners (DP) starting from December 10, 2020 (Table 4). Data cutoff dates for the sources were as
135 follows: DP1 (August 21, 2021), DP2 (July 10, 2021), DP3 (July 31, 2021), and DP4 (June 30, 2021). The
136 age-specific vaccine-attributable incidences of myocarditis/pericarditis were calculated for dose 2 and
137 used as the model input for the risk of individuals with complete two dose vaccination. The risk post
138 dose 1 was ignored since CDC has suggested people who have myocarditis after dose 1 to have a
139 precaution to receive dose 2, and the majority the myocarditis cases were reported post dose 2. For
140 Scenarios 1, 2, 3, and 4 we used the mean meta-analysis predicted myocarditis/pericarditis rate for
141 each male age group, while for Scenario 5 we use the 2.5th percentile rate and for Scenario 6 we used
142 the 97.5th percentile rate. We used Equation 1 to calculate total myocarditis/pericarditis (M_{Pred}) per one
143 million individuals who completed primary vaccination series (two doses of vaccine).

144

$M_{Pred} = M_{Pred2} * F$	Eq. 1
----------------------------	-------

145

146 M_{Pred2} is the meta-analysis estimated myocarditis/pericarditis case rates post dose 2. As presented
147 previously⁶, these rates given in units of per 100k person-years were divided by 365 days and multiplied
148 by 7 days (the risk window), which derives the total number of myocarditis/pericarditis cases within a
149 7-days risk window among the 100k people who completed their primary vaccination series. Next, we
150 multiplied that number by 10 and derived the total number of cases among one million individuals who
151 completed their primary vaccination series. Consequently, when converting from 100k person-years to
152 one million vaccinated individuals' risk post vaccination (in a 7-day risk window), the rates were

153 multiplied by a factor $F = (7*10)/365$ as seen in Equation 1. We calculated the confidence intervals for
154 the myocarditis cases with the chi-square method for Poisson distribution of rare events¹². The number
155 of myocarditis hospitalization (M_H), ICU visits (M_{ICU}), and deaths (M_D) are fractions of predicted
156 myocarditis/pericarditis cases (M_{Pred}), such that $M_H = M_{Pred} * F_H$, $M_{ICU} = M_{Pred} * F_{ICU}$, and $M_D = M_{Pred} * F_D$
157 where the scalars F_H , F_{ICU} , and F_D here are fractions of myocarditis cases that result in the more severe
158 outcomes: hospitalizations, ICU visits, and deaths, respectively.

159 2.3.2. Data and assumptions

160 2.3.2.1. Myocarditis/pericarditis attributable to vaccine

161 We used myocarditis/pericarditis incidence data for male age groups derived from four BEST health
162 claim databases (Table 4). **Meta-analysis results are available for the incidence of myocarditis case rates**
163 **within the risk window of 7 days by vaccine dose 1 and 2 separately.** We limited this study to males 18-
164 64 because the reported cases of myocarditis/pericarditis attributable to vaccine among female age
165 groups and male and female age 65 years or above are very rare, leading to unstable estimates of case
166 rates. Therefore, we are not able to provide reliable estimates of the risks for females in all age groups
167 and individuals 65 years of age and above. Previous work on other mRNA vaccines has shown that the
168 risks are lower for females and those over 65¹⁵.

169 2.3.2.2. Myocarditis/pericarditis hospitalization and death rate

170 Vaccine Safety Datalink (VSD, a vaccine safety monitoring partnership between the CDC and 9
171 integrated healthcare organizations) data¹³ showed that 86% of myocarditis cases are hospitalized, and
172 none required admission to the ICU for ages 18-29 years. The rate for hospitalization fell to 77% for
173 ages 30-39 years. Since the age ranges in VSD differ from those in our analysis, we made the following
174 adjustment for our age ranges. We used hospitalization rates of 86% for ages 18-25 years, 81.5% (the
175 midpoint between ages 18-29 years and ages 30-39 years in VSD data) for ages 26-35 years, and 77%

176 for ages 36 years and above in our analysis. The hospitalizations were mainly for monitoring patients'
177 condition as a precaution and no additional treatment is needed. Vaccine Safety Datalink (VSD) data
178 show a median of a one-day stay during hospitalization¹³. No death confirmed to be caused by vaccine-
179 attributable myocarditis/pericarditis has been identified. In this model, we used zero-death rate for
180 vaccine attributable myocarditis/pericarditis as a model input.

181 3. Results

182 For Scenario 1 (base scenario), the model predicted that vaccination of 1 million males 18-25 years of
183 age with two primary series doses of the vaccine would prevent 82,484 COVID-19 cases, 4,766
184 hospitalizations, 1,144 ICU admissions and 51 deaths due to COVID-19, while causing 128 vaccine-
185 attributable myocarditis/pericarditis cases, 110 hospitalizations and no ICU admissions. No death due
186 to vaccine attributed myocarditis/pericarditis is expected. These results represented the benefit-risk of
187 the groups with the highest potential myocarditis/pericarditis risk under the current scenario (Omicron
188 dominant, most recent peak incidence, and the mean rate of vaccine-attributable
189 myocarditis/pericarditis case), and we considered that the benefits of vaccine clearly outweigh the
190 risks. The results for all six model scenarios are summarized in Table 2, and we considered that the
191 benefits of vaccine clearly outweigh the risks for each of the additional 5 scenarios as well. Scenarios 1,
192 2, and 3 represented the uncertainty in the case incidence (the week of December 25, 2021, average
193 and the lowest incidence) in the future of the pandemic, Scenarios 1 and 4 represented the uncertainty
194 in VE against the emerging variants (Omicron vs Delta), and Scenarios 1, 5, and 6 represented the
195 uncertainty in the incidence rate of vaccine-attributable myocarditis/pericarditis.

196 4. Conclusions and Discussion

197 Based on available data, our results support the conclusion that the benefits of the Moderna vaccine

198 clearly outweigh its risks for all the model scenarios for all males 18-64 years of age. Furthermore,
199 based on consistent evidence that indicates a lower risk of vaccine-associated myocarditis in females of
200 all ages and in males 65 years and older, it is reasonable to expect that the benefit-risk balance of
201 vaccination with Moderna in these demographic groups would be even more favorable compared with
202 males 18-64 years of age. Therefore, we concluded the benefits of the Moderna vaccine outweigh its
203 risks for the overall target population.

204 Our modeling approach has a few limitations in the estimation of benefits. In this analysis, we
205 conducted sensitivity analyses to test the impact of the COVID-19 incidence rates at the recent peak,
206 average, and lowest incidence level of the pandemic. Nevertheless, given the uncertain trajectory of
207 the pandemic, our constant COVID-19 incidence rate assumption creates high uncertainty on the
208 benefit estimates. Furthermore, the percentage of hospitalizations resulting in ICU admission and the
209 percentage of hospitalized patients who die are estimated based on cumulative rates of
210 hospitalizations, ICU admissions, and deaths for each age group reported on COVID-NET from March
211 2020 to October 2021 (pre-Omicron period). The COVID-19 incidence rate might have changed since
212 Omicron surged, but the more recent data were not yet available at the time of this analysis. The rate
213 of ICU admission and death associated with Omicron may be lower compared to Delta, which may lead
214 to overestimation of the benefits.

215 Also, estimated benefits of the vaccine would decrease if the vaccine became less effective against
216 emerging SARS-CoV-2 variants. In this analysis, we evaluated the impact of different VEs for Omicron
217 and Delta strains. However, there is uncertainty associated with future new variants or composition of
218 the variants. Furthermore, the 30% VE for Omicron used in this analysis was obtained from a UK study.
219 A similar US study with a smaller sample size showed an approximately 23% VE for Omicron within a 5-
220 month period post second dose¹⁴. However, we do not expect that this difference in VE estimates
221 would change our B-R conclusion. Another uncertainty for the model is vaccine protection durability. In

222 this analysis, we assumed a 5-month protection period after completion of two primary doses of the
223 vaccine overall. If vaccine-induced immunity significantly wanes within five months post second dose,
224 potentially differentially for infection versus serious disease, that may reduce the benefit of the
225 vaccine. Another limitation to the benefits is that we do not factor in the potential for a COVID-19
226 infection to impart additional protection. Antibody seroprevalence and its correlation to protection are
227 not well understood yet. This could lead to an overestimation of the benefits of the vaccine. We
228 assumed that the vaccine effectiveness against death would be equal to the vaccine effectiveness
229 against COVID-19 hospitalizations in all scenarios. This could lead to underestimation of the benefits.

230 Our approach in estimating risks has limitations as well. First, neither the female group nor age 65
231 years or older of both sexes were included in this analysis due to the rarity of cases of
232 myocarditis/pericarditis in these populations leading to an unstable estimate of case rate. However,
233 the B-R for females and individuals 65 years of age or older is expected to be more favorable compared
234 to male age 18-65 years, for whom clear favorable benefit-risk was demonstrated by this analysis.
235 Second, there is uncertainty in the risk of myocarditis cases attributable to the vaccine. To estimate
236 myocarditis/pericarditis risk attributable to the vaccine, health claims data were used, which have
237 inherent limitations such as small sample sizes due to rare events among age groups. The reported
238 cases in BEST had not been validated by a complete review of the patients' medical charts, and
239 therefore may be an overestimate. To address some of these limitations, the crude myocarditis rate in
240 our model was adjusted using the myocarditis background rate in 2019 (measured by the BEST data
241 partners), meta-analysis of four claims databases was conducted to increase the sample size, and a
242 sensitivity analysis was conducted to test the impact on the benefit-risk of confidence interval of the
243 estimated vaccine-attributable myocarditis/pericarditis case rate. Also, we use VSD data to calculate
244 the rates of hospitalization and death associated with vaccine-attributable myocarditis/pericarditis.
245 However, the actual rates we used for myocarditis came from the FDA's BEST system, not VSD. The

246 reason for this was that the VSD did not provide an age/sex specific myocarditis/pericarditis rate, and
247 the young male group was our primary concern for the mRNA-based vaccine review. The BEST system,
248 on the other hand, lacked information on hospitalizations and deaths caused by vaccine-attributable
249 myocarditis and pericarditis. We did not estimate the proportions' accuracy, which is especially
250 important because the rates of myocarditis for VSD and BEST can differ.

251 Furthermore, some benefit-risk endpoints in our assessment are difficult to compare directly, for
252 example, hospitalizations from COVID-19 and myocarditis hospitalizations. Our B-R assessment did not
253 include potential long-term adverse effects due to either COVID-19 or myocarditis and second-order
254 benefits and risks including potential impact on the public trust in COVID-19 vaccines. In this analysis,
255 we did not investigate the benefits and risks for specific subpopulations, such as those with
256 comorbidities, due to limited information for these populations. Health condition of individuals may
257 remarkably impact the B-R profile and its evaluation.

258 Our model and analyses helped inform FDA's licensure decision on Moderna's vaccine. FDA
259 considered the impact of COVID-19 pandemic on the public health, unavailability of treatment options,
260 urgent need for a vaccine to prevent the disease and control the pandemic, together with available
261 evidence and uncertainty associated with vaccine effectiveness and vaccine-attributable
262 myocarditis/pericarditis risk. The FDA Review Committee agreed that the benefit/risk balance for the
263 vaccine was favorable and supported approval for use of a 2-dose primary series in individuals 18 years
264 of age and older¹⁷. The purpose for publication of this benefit-risk assessment is to increase the
265 transparency of our regulatory action, communicating to the public that benefits of vaccination with
266 the Moderna COVID-19 Vaccine clearly outweigh the risks even among the male adolescent population
267 that is at a higher risk of myocarditis/pericarditis. This will hopefully increase public confidence in the
268 vaccine and promote vaccination to fight COVID-19.

269 5. Acknowledgements

270 We thank Christian Reed, Ph.D., Rituparna Moitra, Ph.D., and Rosser Matthews, Ph.D. for editing this
271 manuscript. We thank Joyce Obidi, Ph.D., and Hui-Lee Wong, Ph.D. for helpful discussions. We thank,
272 Diane Gubernot, Ph.D. and Marisabel Rodriguez Messan, Ph.D. for reviewing the manuscript. We thank
273 FDA CBER OBPV data and analysis partners ACUMEN and OPTUM. Also, we thank the Centers for
274 Disease Control and Prevention, particularly the Vaccine Task Force, for sharing initial benefit-risk
275 assessment model and data on COVID-19 pandemic.

276 Conflict of Interest Statement

277 The authors declare that they have no conflicts of interest relevant to the manuscript submitted to
278 VACCINE X. We confirm that all authors attest they meet the ICMJE criteria for authorship.

279 References

- 280 1. Marshall M, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-
281 BioNTech COVID-19 vaccination. *Pediatrics*. 2021;2. <https://doi.org/10.1542/peds.2021-052478>.
- 282 2. Shay DK, Tom T. Shimabukuro, and Frank DeStefano. Myocarditis occurring after immunization
283 with mRNA-based COVID-19 vaccines. *JAMA cardiology*. 2021.
284 <https://doi.org/10.1001/jamacardio.2021.2821>.
- 285 3. Watkins K, et al. Myocarditis after BNT162b2 vaccination in a healthy male. *The American*
286 *Journal of Emergency Medicine*. 2021. <https://doi.org/10.1016/j.ajem.2021.06.051>.
- 287 4. Centers for Disease Control and Prevention. Population-Level Risk-Benefit Analysis. *5 May*
288 *2021*, <https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/risk-benefit-analysis.html>.
289 2021.
- 290 5. US Food and Drug Administration, “Structured Approach to Benefit-Risk Assessment in Drug
291 Regulatory Decision-Making” available at <https://www.fda.gov/media/84831/download>.
- 292 6. Funk, PR, et al. Benefit-Risk Assessment of COVID-19 Vaccine, mRNA (Comirnaty) for Age 16-29
293 years. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2022.03.030>, 2022.
- 294 7. COVID-NET. A weekly summary of U.S. COVID-19 Hospitalization Data – Laboratory-Confirmed
295 COVID-19 Associated Hospitalizations. *Retrieved December 31, 2021, from*
296 https://gis.cdc.gov/grasp/COVIDNet/COVID19_3.html. 2021.
- 297 8. COVID Data Tracker. COVID-19 Weekly Cases and Deaths per 100,000 Population by Age,
298 Race/Ethnicity, and Sex. *Retrieved December 31, 2021, from* [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#demographicvertime)
299 [tracker/#demographicvertime](https://covid.cdc.gov/covid-data-tracker/#demographicvertime). 2021.

- 300 9. UKHSA (UK Health Security Agency). December 31. SARS-CoV-2 variants of concern and variants
301 under investigation in England Technical briefing: Update on hospitalization and vaccine effectiveness
302 for Omicron VOC-21NOV-01 (B.1.1.529). Retrieved December 31, 2021, from
303 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf)
304 [045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1045619/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf). 2021.
- 305 10. Jones J. COVID-19 Vaccine Effectiveness for Moderna and Janssen Vaccines. ACIP meeting
306 October 21, 2021, Retrieved December 17, 2021, from
307 [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/10-COVID-jones-](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/10-COVID-jones-508.pdf)
308 [508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/10-COVID-jones-508.pdf). 2021.
- 309 11. Oliver S. Updates to the Evidence to Recommendation Framework: Pfizer-BioNTech and
310 Moderna COVID-19 vaccine booster doses. retrieved on November 22, 2021, from
311 <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-19/06-COVID-Oliver-508.pdf>
312 2021.
- 313 12. Garwood F-. Fiducial limits for the Poisson distribution. *Biometrika* 1936;28.3/4:437-42.
- 314 13. Klein N. Rapid Cycle Analysis to Monitor the Safety of COVID-19 Vaccines in Near Real-Time
315 within the Vaccine Safety Datalink: Myocarditis and Anaphylaxis. ACIP Meeting August 30, 2021,
316 Retrieved February 4, 2022 from [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/04-COVID-Klein-508.pdf)
317 [2021-08-30/04-COVID-Klein-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-08-30/04-COVID-Klein-508.pdf).
- 318 14. Tseng, H.F., Ackerson, B.K., Luo, Y. et al. Effectiveness of mRNA-1273 against SARS-CoV-2
319 Omicron and Delta variants. *Nat Med* (2022). <https://doi.org/10.1038/s41591-022-01753-y>
- 320 15. Rosenblum, H., COVID-19 Vaccines in Adults: Benefit-Risk Discussion, ACIP Presentation July 22,
321 2021. Retrieved from [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/05-](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/05-COVID-Rosenblum-508.pdf)
322 [COVID-Rosenblum-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/05-COVID-Rosenblum-508.pdf).
- 323 16. US FDA Guidance. Benefit-Risk Assessment for New Drug and Biological Products 2021. Available
324 from: [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products)
325 [assessment-new-drug-and-biological-products](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products).
- 326 17. US FDA, Summary Basis for Regulatory Action for Spikevax. Available from
327 <https://www.fda.gov/media/155931/download>
328

329 **Table 1. Six model scenarios with varying COVID-19 incidence rates, vaccine effectiveness against cases and**
 330 **hospitalization, and myocarditis/pericarditis rates.**

	COVID-19 Incidence	Vaccine Effectiveness	Excess Myocarditis Risk
Scenario 1	As of December, 2021	Omicron dominant: 30% against cases 72% against hospitalization 72% against death	Mean of BEST meta-analysis
Scenario 2	Average COVID-19 pandemic incidence in 2021	Same as Scenario 1	Same as Scenario 1
Scenario 3	Lowest COVID-19 pandemic incidence (June 5, 2021)	Same as Scenario 1	Same as Scenario 1
Scenario 4	Same as Scenario 1	Delta dominant: 80% against cases 90% against hospitalization 90% against death	Same as Scenario 1
Scenario 5	Same as Scenario 1	Same as Scenario 1	2.5 th percentile of BEST meta-analysis
Scenario 6	Same as Scenario 1	Same as Scenario 1	97.5 th percentile of BEST meta-analysis

331

332

333 **Table 2. Benefit-risk outcomes per million males vaccinated with 2 primary series doses of Moderna CVmRNA**
 334 **under each of six scenarios described in Table 1.**

	Ages	BENEFITS				RISKS			
		COVID	COVID	COVID	COVID	Myo/Peri	Myo/Peri	Myo/Peri	Myo/Peri
		Cases	Hospitalizations	ICUs	Deaths	Cases	Hospitalizations	ICUs	Deaths
Scenario 1	18-25yo	82,484	4,766	1,144	51	128	110	0	0
	26-35yo	87,557	4,766	1,220	247	32	26	0	0
	36-45yo	90,939	4,766	1,258	378	23	18	0	0
	46-55yo	77,624	10,921	3,200	1,423	13	10	0	0
	56-64yo	68,747	15,025	4,928	2,120	10	7	0	0
Scenario 2	18-25yo	26,705	2,088	501	48	128	110	0	0
	26-35yo	29,718	2,088	535	235	32	26	0	0
	36-45yo	31,727	2,088	551	359	23	18	0	0
	46-55yo	29,174	4,607	1,350	1,087	13	10	0	0
	56-64yo	27,472	6,286	2,062	1,573	10	7	0	0
Scenario 3	18-25yo	3,903	635	152	7	128	110	0	0
	26-35yo	4,307	635	163	33	32	26	0	0
	36-45yo	4,576	635	168	50	23	18	0	0
	46-55yo	4,311	1,127	330	158	13	10	0	0
	56-64yo	4,134	1,456	477	230	10	7	0	0
Scenario 4	18-25yo	219,958	5,957	1,430	63	128	110	0	0
	26-35yo	233,486	5,957	1,525	309	32	26	0	0
	36-45yo	242,504	5,957	1,573	472	23	18	0	0
	46-55yo	206,998	13,652	4,000	1,779	13	10	0	0
	56-64yo	183,326	18,781	6,160	2,650	10	7	0	0
Scenario 5	18-25yo	82,484	4,766	1,144	51	68	58	0	0
	26-35yo	87,557	4,766	1,220	247	9	7	0	0
	36-45yo	90,939	4,766	1,258	378	11	9	0	0
	46-55yo	77,624	10,921	3,200	1,423	7	5	0	0
	56-64yo	68,747	15,025	4,928	2,120	4	3	0	0
Scenario 6	18-25yo	82,484	4,766	1,144	51	241	207	0	0
	26-35yo	87,557	4,766	1,220	247	119	97	0	0
	36-45yo	90,939	4,766	1,258	378	47	36	0	0
	46-55yo	77,624	10,921	3,200	1,423	23	18	0	0
	56-64yo	68,747	15,025	4,928	2,120	23	18	0	0

335

336

337 **Table 3. End of December 2021 US COVID incidences in the unvaccinated population listed by age groups (Male**
338 **population only) and percentage of hospitalized going to ICU. Source: 1- COVID Data Tracker, 2-COVID-NET.**

Age group	Daily COVID-19 cases/100k persons¹	Daily Hospitalizations/100k persons²	Daily deaths/100k persons¹	Percent of hospitalized going to ICU²
18-25	180.89	4.35	0.05	24.0
26-35	192.01	4.35	0.23	25.6
36-45	199.43	4.35	0.34	26.4
46-55	170.23	9.98	1.30	29.3
56-64	150.76	13.73	1.94	32.8

339

340

341 **Table 4. Estimated rates of vaccine-attributable myocarditis/pericarditis cases post second dose of the primary**
342 **series, by age subgroup, for 1 million fully vaccinated male individuals with Moderna CVmRNA.**

Age Group	Moderna CVmRNA Adjusted Rate per 1M Doses Point Estimate and 95% CI	Data Source (DP = CBER BEST Data Partner)
18-25	127.8 [67.8, 241.2]	DP1-4
26-35	31.8 [8.5, 118.9]	DP1-4
36-45	23.1 [11.3, 47.2]	DP1-4
46-55	12.5 [6.9, 22.8]	DP1-4
56-64	9.6 [3.9, 23.3]	DP1-4

343

344

345

346 Figure Captions

347 Figure 1. Benefits-risks value tree.

348 Description: A tree from left to right pointing out the benefits and risks of Moderna CVmRNA.

349 Figure 2. Benefit-risk outcomes per million males in age groups within 18-45 years for scenario 1

350 Description: Six bar graphs examining benefits (e.g., prevented deaths) and risks (e.g., excess
351 deaths)

352



